Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike
- DOI
- Language of the publication
- English
- Date
- 2020-10-20
- Type
- Article
- Author(s)
- Prévost, Jérémie
- Gasser, Romain
- Beaudoin-Bussières, Guillaume
- Richard, Jonathan
- Duerr, Ralf
- Laumaea, Annemarie
- Anand, Sai Priya
- Goyette, Guillaume
- Benlarbi, Mehdi
- Ding, Shilei
- Medjahed, Halima
- Lewin, Antoine
- Perreault, Josée
- Tremblay, Tony
- Gendron-Lepage, Gabrielle
- Gauthier, Nicolas
- Carrier, Marc
- Marcoux, Diane
- Piché, Alain
- Lavoie, Myriam
- Benoit, Alexandre
- Loungnarath, Vilayvong
- Brochu, Gino
- Haddad, Elie
- Stacey, Hannah D.
- Miller, Matthew S.
- Desforges, Marc
- Talbot, Pierre J.
- Gould Maule, Graham T.
- Côté, Marceline
- Therrien, Christian
- Serhir, Bouchra
- Bazin, Renée
- Roger, Michel
- Finzi, Andrés
- Publisher
- Elsevier Inc.
Abstract
SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
Subject
- Health
Rights
Pagination
1-8, e1-e4
Peer review
Yes
Open access level
Gold
Identifiers
- PubMed ID
- 33015650
- ISSN
- 2666-3791
Article
- Journal title
- Cell Reports Medicine
- Journal volume
- 1
- Journal issue
- 7
- Article number
- 100126